Clinician’s Guide to Prevention and Treatment of Osteoporosis
Open accessThe DOI matches its Crossref record; 101 of the 102 references it cites were found in a registry or an index; 41 of the 169 sources its claims cite were checked for support.
Abstract
The Clinician's Guide to Prevention and Treatment of Osteoporosis was developed by an expert committee of the National Osteoporosis Foundation (NOF) in collaboration with a multispecialty council of medical experts in the field of bone health convened by NOF. Readers are urged to consult current prescribing information on any drug, device, or procedure discussed in this publication.
Overview
CoChat Summary
TL;DR
This NOF Clinician’s Guide provides recommendations for prevention, risk assessment, diagnosis, and treatment of osteoporosis in postmenopausal women and men age 50 and older, including BMD testing, vertebral imaging, FRAX-based intervention thresholds, and FDA-approved pharmacotherapy. It emphasizes that osteoporosis is common, underdiagnosed, and treatable, with treatment thresholds and drug-specific fracture risk reductions summarized.
Key findings
- Osteoporosis affects more than 9.9 million Americans, with an additional 43.1 million having low bone density; about 1 in 2 Caucasian women and approximately 1 in 5 men will experience an osteoporosis-related fracture. Annually, 2 million fractures are attributed to osteoporosis, causing more than 432,000 hospital admissions, almost 2.5 million medical office visits, and about 180,000 nursing home admissions; costs are expected to rise to $25.3 billion by 2025. Only 23% of women age 67 or older who have an osteoporosis-related fracture receive either a BMD test or a prescription for osteoporosis drug in the 6 months after fracture.
- Pharmacologic treatment is recommended for hip or vertebral fracture, T-score ≤−2.5 at the femoral neck, total hip, or lumbar spine, or low bone mass (T-score between −1.0 and −2.5) with a 10-year hip fracture probability ≥3% or a 10-year major osteoporosis-related fracture probability ≥20% by US-adapted FRAX.
- Universal recommendations include calcium intake of 1000 mg/day for men 50–70 and 1200 mg/day for women 51 and older and men 71 and older; vitamin D 800–1000 IU/day for adults age 50 and older; regular weight-bearing and muscle-strengthening exercise; fall risk assessment and modification; smoking cessation; and avoidance of excessive alcohol.
- Selected drug efficacy data: alendronate reduces spine and hip fractures by about 50% over 3 years; zoledronic acid reduces vertebral fractures by 70%, hip fractures by 41%, and nonvertebral fractures by 25% over 3 years; denosumab reduces vertebral fractures by about 68%, hip fractures by about 40%, and nonvertebral fractures by about 20% over 3 years; teriparatide reduces vertebral fractures by about 65% and nonvertebral fragility fractures by about 53%; raloxifene reduces vertebral fractures by about 30% with prior vertebral fracture and about 55% without; calcitonin reduces vertebral fracture occurrence by about 30% but has not been shown to reduce nonvertebral fractures; ibandronate reduces vertebral fractures by about 50% but nonvertebral fracture reduction has not been documented.
Methods
- Design: guideline developed by an expert committee of the National Osteoporosis Foundation in collaboration with a multispecialty council of medical experts in bone health; recommendations apply to postmenopausal women and men age 50 and older.
- Data or sample: no primary study sample; the Guide synthesizes evidence including NHANES III prevalence estimates, the Women’s Health Initiative, FDA prescribing information, WHO FRAX, and cost-effectiveness analyses.
- Main analysis: expert consensus and evidence synthesis; absolute risk thresholds for pharmacologic intervention were guided by a cost-effectiveness analysis; diagnostic assessment uses central DXA, vertebral imaging, and US-adapted WHO FRAX.
Limitations
- Stated: FRAX underestimates fracture risk in patients with recent fractures, multiple osteoporosis-related fractures, and increased fall risk; it has not been validated for lumbar spine BMD, is not intended for younger adults or children, and has not been validated in patients currently or previously treated with osteoporosis pharmacotherapy.
- Stated: evidence of efficacy beyond 5 years is limited; rare safety concerns such as osteonecrosis of the jaw and atypical femur fractures become more common beyond 5 years; there are relatively few data confirming fracture risk reductions with pharmacotherapy in patients selected by low bone mass plus FRAX thresholds; fracture data are limited in glucocorticoid-induced osteoporosis and in men; and in the absence of head-to-head trials, direct comparisons of risk reduction among drugs should be avoided.
- Evident: the text does not report a systematic search strategy or formal evidence-grading system; the therapeutic thresholds are described as clinical guidance only and “not rules,” requiring individualized clinical judgment.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Micrographs of normal vs. osteoporotic bone [9], from Dempster et al., with permission of The American Society for Bone and Mineral Research [9]](https://figures.cochat.ai/paper-figures/d609b75c87444980afa9b5aebc701061/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-1.jpg)
![Fig. 2 Pathogenesis of osteoporosis-related fractures, from Cooper and Melton, with modification [10]](https://figures.cochat.ai/paper-figures/ff3ff2f3f4b84a5bbd00a8cc79080d62/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-2.jpg)

Verification
Claims the paper makes
29 Valid · 18 Not valid · 68 Not checked · 17 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Raloxifene is also indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis [83–86].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Estrogen agonist/antagonist (formerly known as SERMs): Raloxifene
What the sources say
- Not checked — no full text of the sourcecites [83] Cauley JA Norton L Lippman ME Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation Breast Cancer Res Treat 2001 65 2 125 134 10.1023/A:1006478317173 11261828 source
- Disputedcites [84] Martino S Cauley JA Barrett-Connor E CORE Investigators Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene J Natl Cancer Inst 2004 96 23 1751 1761 10.1093/jnci/djh319 15572757 sourceExperimental — accuracy not yet measured
The introduction (p. 1) says raloxifene was approved for preventing and treating postmenopausal osteoporosis, while tamoxifen was the only agent approved in the United States to reduce breast cancer incidence. Although the CORE results (p. 5) show reduced invasive breast cancer incidence with raloxifene, they do not support the claim that breast cancer risk reduction was an approved indication. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [85] Vogel VG Costantino JP Wickerham DL National Surgical Adjuvent Breast and Bowel Project (NSABP) Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 2006 295 23 2727 2741 10.1001/jama.295.23.joc60074 16754727 source
- Partly supportedcites [86] Barrett-Connor E Mosca L Collins P Raloxifene Use for The Heart (RUTH) Trial Investigators Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women N Engl J Med 2006 355 2 125 137 10.1056/NEJMoa062462 16837676 sourceExperimental — accuracy not yet measured
The Primary Outcomes (p. 5) report that raloxifene reduced invasive breast cancer in the RUTH trial, and the introductory text (p. 2) reports a similar finding from MORE, an osteoporosis-treatment trial. The paper does not state that breast-cancer risk reduction is an approved indication for postmenopausal women with osteoporosis; RUTH enrolled women with or at increased risk for coronary heart disease. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Ibandronate reduces the incidence of vertebral fractures by about 50 % over 3 years, but reduction in risk of nonvertebral fracture with ibandronate has not been documented [50].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Bisphosphonates
What the sources say
- Disputedcites [50] Chesnut CH 3rd Skag A Christiansen C Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J Bone Miner Res 2004 19 18 1241 1249 10.1359/JBMR.040325 15231010 sourceExperimental — accuracy not yet measured
The Clinical osteoporotic nonvertebral fractures section reports a statistically significant 69% reduction with daily ibandronate in women with a baseline femoral-neck BMD T score below −3.0. The Discussion cautions that this was a post hoc analysis and says there was no significant reduction in the overall population, but the unqualified claim that a reduction has not been documented overlooks the reported subgroup finding. Page numbers were not provided in the supplied passages. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A vertebral fracture is consistent with a diagnosis of osteoporosis, even in the absence of a bone density diagnosis, and is an indication for pharmacologic treatment with osteoporosis medication to reduce subsequent fracture risk [18, 21].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Vertebral imaging
What the sources say
- Not checked — no full text of the sourcecites [18] Kanis JA Melton LJ 3rd Christiansen C Johnston CC Khaltaev N The diagnosis of osteoporosis J Bone Miner Res 1994 9 8 1137 1141 10.1002/jbmr.5650090802 7976495 source
- Supportedcites [21] Melton LJ Chrischilles EA Cooper C Lane AW Riggs BL How many women have osteoporosis? J Bone Miner Res 2005 20 5 886 892 10.1359/jbmr.2005.20.5.886 15931736 source
The conclusion (OSTEOPENIA, p. 6) distinguishes osteoporosis assessed by bone mineral measurements from established osteoporosis assessed by the occurrence of specific fractures. The introduction (p. 2) identifies vertebral fractures among the principal osteoporosis-related fractures, supporting the stated diagnosis without a bone-density diagnosis. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Help determine adequacy of patient compliance and persistence with osteoporosis therapy”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The review’s “Compliance and persistence” section describes a model in which a bone turnover marker result could lead to a conclusion that compliance or treatment response was inadequate, but notes that the model did not include test-accuracy data. “Measures of adherence” says that a marker-identified non-response could reflect non-compliance or non-persistence, among several other causes. The source therefore supports markers as a possible clue, not as a way to determine the adequacy of both compliance and persistence. (LLM, conf=0.83)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Predict magnitude of BMD increases with FDA-approved therapies”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The Clinical Effectiveness and Cost-Effectiveness Evidence section reports correlations between changes in bone turnover markers and BMD, including a statistically significant but weak correlation during teriparatide treatment. It also says not all correlations were significant and cautions that their usefulness varies by population. The review does not establish that markers predict the magnitude of BMD increases across FDA-approved therapies generally. (LLM, conf=0.84)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
87 more claims · 25 with their cited sources checked
Create a free account to see all 132 claims and to verify the 18 references still open.
- Probably not a substantial claim. 26
- It may state two separate claims as one. 25
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“this equated to a health care cost of $1088”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Previous studies31,46,47,48 in emergency department patients have identified primarily benefits, including reductions in health care costs, medical retirement, and depressive symptoms.”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredIn the citing paper
“yielding an uptake of 89.9%”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
In the citing paper
“this issue was addressed by instead performing a thorough cost accounting from 2 specific exemplar interventions.30,31”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Diagnostic assessment
“Screening BMD and vertebral imaging recommendations for men are outlined in Table 8.”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Additional bone densitometry technologies
“Table: Table 8 Additional bone densitometry technologies”
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Incidence and Economic Burden of Osteoporosis-Related Fractures in the United States, 2005–2025
Burge, R., Dawson-Hughes, B., Solomon, D. H., Wong, J. B., King, A., & Tosteson, A. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.061113 · Cited by 4,026
Interventions for preventing falls in older people living in the community
Gillespie, L. D., Robertson, M. C., Gillespie, W. J., Sherrington, C., Gates, S., Clemson, L., & Lamb, S. E. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007146.pub3 · Cited by 3,966
Professor Kanis, J. A., Melton, L. J., Christiansen, C., Johnston, C. C., & Khaltaev, N. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090802 · Cited by 3,849
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489 · cited 1×
“by about 40 %, and nonvertebral fractures by about 20 % over 3 years [56].”
BackgroundDecreased bioavailability of vitamin D in obesity
Wortsman, J., Matsuoka, L. Y., Chen, T. C., Lu, Z., & Holick, M. F. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/72.3.690 · Cited by 3,204 · cited 1×
“This regimen should be followed by maintenance therapy of 1500–2000 IU/day or whatever dose is needed to maintain the target blood level [37, 38].”
Background
Research works printed but not linked: 4
- Office of the Surgeon General (US) (2004) Bone health and osteoporosis: a report of the Surgeon General. Office of the Surgeon General (US), Rockville (MD). Available from: http://www.ncbi.nlm.nih.gov/books/NBK45513/. Accessed March 2014 20945569
- National Osteoporosis Foundation Physician’s guide to prevention and treatment of osteoporosis 2005 Washington, DC National Osteoporosis Foundation
- Institute of Medicine (US) Committee to review dietary reference intakes for vitamin D and calcium (2011). In: Ross AC, Taylor CL, Yaktine AL et al (eds) Dietary reference intakes for calcium and vitamin D. National Academies Press (US), Washington (DC). Available from: http://www.ncbi.nlm.nih.gov/books/NBK56070/. Accessed March 2014 21796828
- Cummings, SR, San Martin J, McClung MR et al (2009) FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756–765. (Erratum in: N Engl J Med. 2009;36(10):191) 19671655 · DOI · Paper page
Cited by
Items 1,201–1,300 of 4,108
Burden of osteoporosis in Vietnam: An analysis of population risk
Hoang, D. K., Doan, M. C., Linh, D. N. P., Ho-Le, T. P., & Ho-Pham, L. T. (2021) · PLoS ONE · doi:10.1371/journal.pone.0252592 · Cited by 33
“In summary, we found almost half of women and one-third of men aged 50+ years of Viet- namese background would be eligible for treatment by the NOF guidelines.”
BackgroundMethodInfluentialDou, J., Wang, J., & Zhang, Q. (2021) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-021-00687-8 · Cited by 21
“The National Osteoporosis Foundation guidelines, therefore, suggested that screening for osteoporosis should be conducted for general women aged ≥ 65 years and men aged ≥ 70 years to prevent the morbidity and mortality related to fractures [18].”
BackgroundSclerostin Inhibition: A Novel Target for the Treatment of Postmenopausal Osteoporosis
Aditya, S., & Rattan, A. (2021) · Journal of Mid-life Health · doi:10.4103/jmh.jmh_106_20 · Cited by 30
“[17] While sequential treatment of teriparatide (anabolic) followed by an antiresorptive medication is approved, combination therapy is not endorsed due to less supportive data, high cost, and side effects.[8] Teriparatide, denosumab, or zoledronic acid is considered for those at high fracture risk unable to use oral…”
BackgroundInfluentialStudy on synergistic effects of carboxymethyl cellulose and LIPUS for bone tissue engineering
Tang, L., Wu, T., Zhou, Y., Zhong, Y., Sun, L., Guo, J., Fan, X., & Ta, D. (2022) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2022.119278 · Cited by 20
Harahap, I. A., Kuligowski, M., SCHMIDT, M. T., & Suliburska, J. (2023) · Food Chemistry Advances · doi:10.1016/j.focha.2023.100269 · Cited by 22
Ting, M., Huynh, B. H., Woldu, H. G., El-Hussein, I. G., & Suzuki, J. B. (2023) · Journal of Oral Implantology · doi:10.1563/aaid-joi-d-21-00160 · Cited by 25
Porous metal materials for applications in orthopedic field: A review on mechanisms in bone healing
Ma, Y., Wang, Y., Tong, S., Wang, Y., Wang, Z., Sui, R., Yang, K., Witte, F., & Yang, S. (2024) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2024.08.003 · Cited by 32
“The activation of AMPK also inhibits mevalonate, promoting the differentiation of osteoblast. osteoclastogenesis, exacerbating bone loss through increased resorption and decreased formation [191,192].”
Overdiagnosis of osteoporosis: fact or fallacy?
Compston, J. E. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3220-0 · Cited by 20
Crandall, C. J., Hovey, K. M., Andrews, C., Cauley, J. A., Manson, J. E., Wactawski‐Wende, J., Wright, N. C., Li, W., Beavers, K. M., Curtis, J. R., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2568 · Cited by 21
Self-citationMonoclonal antibodies for the treatment of osteoporosis
Lewiecki, E. M. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.740006 · Cited by 21
Self-citationMokhtarzadeh, H., & Anderson, D. (2016) · Current Osteoporosis Reports · doi:10.1007/s11914-016-0305-4 · Cited by 22
Before the breaking point: reducing the risk of osteoporotic fracture.
Forstein, D. A., Bernardini, C., Cole, R. E., Harris, S. T., & Singer, A. J. (2013) · PubMed · Cited by 19
Wearable technology for the elderly: Underutilized solutions
Hentschel, M. A., Haaksma, M. L., & van de Belt, T. H. (2016) · European Geriatric Medicine · doi:10.1016/j.eurger.2016.07.008 · Cited by 22
Body composition in HIV-infected patients receiving highly active antiretroviral therapy
Chițu, C. E., Barbu, E. C., Lazăr, M., Bojincă, M., Tudor, A. M., Hristea, A., Abagiu, A. O., Ion, D. A., & Bădărău, A. I. (2016) · Acta Clinica Belgica · doi:10.1080/17843286.2016.1240426 · Cited by 20
Carlson, B. C., Robinson, W. A., Wanderman, N. R., Nassr, A. N., Huddleston, P. M., Yaszemski, M. J., Currier, B. L., Jeray, K. J., Kirk, K. L., Bunta, A. D., et al. (2018) · Osteoporosis International · doi:10.1007/s00198-018-4585-7 · Cited by 21
Ahmadieh, H., Basho, A., Chehade, A., et al. (2018) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2018.10.001 · Cited by 20
Su, Y., Woo, J., & Kwok, T. C. Y. (2018) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2018.08.007 · Cited by 19
Ahmad, A., & Ahmed, Z. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815260-7.00003-1 · Cited by 30
Acromial Stress Fractures: A Systematic Review.
LUCASTI, C. J., & Namdari, S. (2019) · PubMed · doi:10.22038/abjs.2019.36735.1970 · Cited by 20
Use of anti-osteoporosis medication dispensing by patients with hip fracture: could we do better?
Kristensen, P. K., Ehrenstein, V., Shetty, N., & Pedersen, A. B. (2019) · Osteoporosis International · doi:10.1007/s00198-019-05066-8 · Cited by 22
You, R., Zhang, Y., Wu, D. B.-C., Liu, J., Qian, X., Luo, N., & Mori, T. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00456 · Cited by 22
Asgari, M., Gazor, R., Abdollahifar, M., Fathabady, F. F., Zare, F., Norouzian, M., Amini, A., Khosravipour, A., Kiani, P., Atashgah, R. B., et al. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.06.023 · Cited by 20
Nowakowska-Płaza, A., Wroński, J., Sudoł‐Szopińska, I., & Głuszko, P. (2021) · Hormone and Metabolic Research · doi:10.1055/a-1528-7261 · Cited by 24
“The fractures associated with osteoporosis result in disability, impaired quality of life, increased mortality, and are a tremendous burden, both personal and economic [3].”
BackgroundKim, J. W., Koh, J., Park, J. H., & Chang, J. S. (2015) · Bone · doi:10.1016/j.bone.2015.02.013 · Cited by 21
Božič, M., & Hren, N. I. (2013) · Journal of Cranio-Maxillofacial Surgery · doi:10.1016/j.jcms.2013.01.033 · Cited by 19
Regulatory aspects of the development of drugs for metabolic bone diseases – FDA and EMA perspective
Kehoe, T. E., BLIND, E., & Janssen, H. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13791 · Cited by 18
Zhang, W., Liu, S., Liu, X., et al. (2021) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-021-02219-6 · Cited by 19
Approaches to Fracture Risk Assessment and Prevention
Baim, S., & Blank, R. D. (2021) · Current Osteoporosis Reports · doi:10.1007/s11914-021-00659-x · Cited by 19
Huo, S., Liu, X., Zhang, S., Lyu, Z., Zhang, J., Wang, Y., Nie, B., & Yue, B. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107458 · Cited by 22
Yang, X., Tang, W., Mao, D., Shu, Q., Yin, H., Tang, C., Zhang, M., Li, C., & Ding, X. (2021) · Archives of Osteoporosis · doi:10.1007/s11657-021-00910-z · Cited by 22
Efficacy and Safety of Denosumab in Osteoporosis or Low Bone Mineral Density Postmenopausal Women
Chen, Y., Zhu, J. W., Zhou, Y., Peng, J., & Wang, B. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.588095 · Cited by 24
“Osteoporosis can occur as part of the aging process or secondarily due to nutritional deficiency, metabolic disorders, or medication side effects (National Library of Medicine, 2010; Cosman et al., 2014).”
BackgroundThe Skeletal Effects of Tanshinones: A Review
Ekeuku, S. O., Pang, K.-L., & Chin, K. (2021) · Molecules · doi:10.3390/molecules26082319 · Cited by 19
“Osteoporosis frequently remains undiagnosed due to its asymptomatic nature until it presents as low-trauma hip, spine, proximal humerus, pelvis and/or wrist fractures [4,5].”
BackgroundMatovu, F. K., Kiwanuka, N., Nabwana, M., et al. (2022) · The Lancet Global Health · doi:10.1016/s2214-109x(22)00080-8 · Cited by 19
Benjawan, S., Nimitphong, H., Tragulpiankit, P., Musigavong, O., Prathanturarug, S., & Pathomwichaiwat, T. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154115 · Cited by 22
Clinical risk factor status in patients with vertebral fracture but normal bone mineral density
Kadri, A., Binkley, N., Daffner, S. D., & Anderson, P. A. (2022) · The Spine Journal · doi:10.1016/j.spinee.2022.05.019 · Cited by 18
Manaye, S., Cheran, K., Murthy, C., Bornemann, E. A., Kamma, H. K., Alabbas, M., Elashahab, M., Abid, N., & Franchini, A. P. A. (2023) · Cureus · doi:10.7759/cureus.34644 · Cited by 22
“Popularly known as the silent disease, osteoporosis is usually only diagnosed following fractures that occur with minimal or no trauma [2].”
BackgroundInfluentialLee, M.-T., Fu, S., Hsu, C., Chen, H., Lin, J., Tsai, K., Hwang, J., Lin, S.-C., Wu, C., & Wang, C. (2023) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2023.05.001 · Cited by 21
Osteoporosis in the Setting of Shoulder Arthroplasty: A Narrative Review
Daher, M., Fares, M. Y., Boufadel, P., Khanna, A., Zalaquett, Z., & Abboud, J. A. (2023) · Geriatric Orthopaedic Surgery & Rehabilitation · doi:10.1177/21514593231182527 · Cited by 19
“Although the side effects of bisphosphonates are rare, they are important and include gastrointestinal inflammation, atypical femur fractures, and jaw osteonecrosis.(11) In this retrospective study, there was no data about the outcomes of these treated patients.”
BackgroundBone Health in Adults Treated with Endocrine Therapy for Early Breast or Prostate Cancer
Poznak, C. H. V. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e567 · Cited by 21
Bone mineral density and the risk of breast cancer: a case-control study of Korean women
Kim, B.-K., Choi, Y., Song, Y., Park, J., Noh, H., Nguyen, T. L., & Hopper, J. L. (2013) · Annals of Epidemiology · doi:10.1016/j.annepidem.2013.11.009 · Cited by 24
Non-adherence to anti-osteoporotic medications in Taiwan: physician specialty makes a difference
Yu, S., Yang, T.-S., Chiu, W.-C., Hsu, C., Chou, C., Su, Y., Lai, H., Chen, Y., Chen, C., & Cheng, T. (2013) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-013-0424-2 · Cited by 19
Stephens, M., Grey, A., Fernandez, J., Kalluru, R., Faasse, K., Horne, A., & Petrie, K. (2016) · Psychology and Health · doi:10.1080/08870446.2015.1112389 · Cited by 20
Time to Osteoporosis and Major Fracture in Older Men
Gourlay, M. L., Overman, R. A., Fine, J. P., Filteau, G., Cawthon, P. M., Schousboe, J. T., ORWOLL, E. S., Wilt, T. J., Nguyen, T. V., Lane, N. E., et al. (2016) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2015.11.015 · Cited by 23
LaFleur, J., Rillamas‐Sun, E., Colon-Emeric, C. S., Knippenberg, K., Ensrud, K. E., Gray, S. L., Cauley, J. A., & LaCroix, A. Z. (2016) · The Gerontologist · doi:10.1093/geront/gnv677 · Cited by 22
The Bone Health Team: A Team-Based Approach to Improving Osteoporosis Care for Primary Care Patients
Lawrence, P. T., Grotzke, M. P., Rosenblum, Y., Nelson, R. E., LaFleur, J., Miller, K. L., Ma, J., & Cannon, G. W. (2017) · Journal of Primary Care & Community Health · doi:10.1177/2150131916687888 · Cited by 23
Nogués, X., Prieto‐Alhambra, D., Güerri‐Fernández, R., García‐Giralt, N., Rodríguez‐Morera, J., Cos, M. L., Mellibovsky, L., & Díez‐Pérez, A. (2017) · Bone · doi:10.1016/j.bone.2017.06.018 · Cited by 20
Health Maintenance in Inflammatory Bowel Disease
Mir, F., & Kane, S. V. (2018) · Current Gastroenterology Reports · doi:10.1007/s11894-018-0621-1 · Cited by 20
Medical and Musculoskeletal Concerns for the Wheelchair Athlete: A Review of Preventative Strategies
Dutton, R. A. (2019) · Current Sports Medicine Reports · doi:10.1249/jsr.0000000000000560 · Cited by 21
Millen, A. E., Nie, J., Mares, J. A., Lutsey, P. L., LaMonte, M. J., Meuer, S. M., Sahli, M. W., Andrews, C., Klein, R., & Klein, R. (2019) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.18-25945 · Cited by 22
Dilemma of Gonial Angle in Sex Determination
Bulut, Ö., Thiemann, N., Hekįmoğlu, B., et al. (2019) · American Journal of Forensic Medicine & Pathology · doi:10.1097/paf.0000000000000500 · Cited by 19
Thu, W. P. P., Logan, S. J. S., Cauley, J. A., Kramer, M. S., & Yong, E. (2019) · Archives of Osteoporosis · doi:10.1007/s11657-019-0631-0 · Cited by 20
Zhao, C., Liu, G., Zhang, Y., Xu, G., Yi, X., Liang, J., Yang, Y., Liang, J., Ma, C., Ye, Y., et al. (2019) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.23112 · Cited by 22
Xiao, K.-W., Li, J.-L., Zeng, Z., Liu, Z., Hou, Z., Yan, X., & Cai, L. (2019) · Scientific Reports · doi:10.1038/s41598-019-53843-6 · Cited by 22
Hoffmann, P., Krisam, J., Kasperk, C. H., & Gauss, A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8122178 · Cited by 22
Use of age-dependent FRAX-based intervention thresholds for Singapore
Kanis, J. А., Chandran, M., Chionh, S. B., Ganeson, G., Harvey, N. C., Koh, W., Kwok, T. C. Y., Lau, T. C., Liu, E., Lorentzon, M., et al. (2020) · Archives of Osteoporosis · doi:10.1007/s11657-020-00782-9 · Cited by 20
Rendina, D., D’Elia, L., Evangelista, M., FILIPPO, G. D., Giaquinto, A., Barone, B., Piccinocchi, G., Prezioso, D., & Strazzullo, P. (2020) · Calcified Tissue International · doi:10.1007/s00223-020-00737-9 · Cited by 21
Lee, B.-J., Koo, H.-W., Yoon, S., & Sohn, M.-J. (2020) · Spine · doi:10.1097/brs.0000000000003756 · Cited by 6
“Generally, osteoporosis increases with age as bone strength decreases, which in turn increases the incidence of low energy fractures.(2,3) With the increase in the elderly population, the incidence of osteoporotic compression fractures is also increasing every year, leading to a decrease in the quality of life and inc…”
BackgroundOsteoporosis Is Undertreated After Low-energy Vertebral Compression Fractures
Haffner, M. R., Delman, C. M., Wick, J. B., Han, G. T., Roberto, R. F., Javidan, Y., Klineberg, E. O., & Le, H. V. (2021) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/jaaos-d-20-01132 · Cited by 22
Ahn, G. Y., Kim, S. E., Yun, T. H., Choi, I., Park, D., & Choi, S. (2021) · Biomaterials Research · doi:10.1186/s40824-021-00231-9 · Cited by 19
Li, Y., Tung, K., Cho, Y.-C., Lin, S., Lee, C.-H., & Chen, C. (2022) · BMC Geriatrics · doi:10.1186/s12877-022-03014-6 · Cited by 18
Mannino, F., D’Angelo, T., Pallio, G., Ieni, A., Pirrotta, I., Giorgi, D. A., Scarfone, A., Mazziotti, S., Booz, C., Bitto, A., et al. (2022) · Nutrients · doi:10.3390/nu14204296 · Cited by 20
“For this reason, RANKL represents a pharmacological target, and denosumab is prescribed as a RANKL inhibitor for the management of osteoporosis, despite its use as well as that of other anti-osteoporotic drugs, such as bisphosphonates and calcitonin, is related to adverse effects and regular infusion appointments are…”
BackgroundInfluentialPark, H. A., & Kim, S. Y. (2013) · Journal of Korean Medical Association · doi:10.5124/jkma.2013.56.4.310 · Cited by 21
Bertonazzi, A., Nelson, B., Salvador, J., & Umland, E. M. (2015) · Women s Health · doi:10.2217/whe.15.64 · Cited by 20
Access to Anti-osteoporosis Medication after Hip Fracture in Korean Elderly Patients
Yu, Y. M., Lee, J., & Lee, E. (2017) · Maturitas · doi:10.1016/j.maturitas.2017.06.021 · Cited by 19
Contemporary Lifestyle Modification Interventions to Improve Metabolic Comorbidities in HIV
Fitch, K. V. (2019) · Current HIV/AIDS Reports · doi:10.1007/s11904-019-00467-0 · Cited by 21
Leslie, W. D., Morin, S. N., Lix, L. M., & Binkley, N. (2019) · Archives of Osteoporosis · doi:10.1007/s11657-019-0660-8 · Cited by 20
Martini, M. L., Mikula, A. L., Lakomkin, N., Pennington, Z. A., Everson, M. C., Hamouda, A. M., Bydon, M., Freedman, B. A., Sebastian, A. S., Nassr, A. N., et al. (2023) · Spine · doi:10.1097/brs.0000000000004822 · Cited by 20
“10,11,29,30 To this end, this current study is the fi rst to show that opportunistic CT-based HUs strongly correlate with FDA-approved BCT-based measures, while neither correlate strongly with DXA-based BMD measures in the thoracolumbar spine.”
Updates on the Role of DXA in the Evaluation and Monitoring of Osteoporosis
Anupama, S., Lim, S. Y., & Bolster, M. B. (2025) · Current Rheumatology Reports · doi:10.1007/s11926-025-01205-9 · Cited by 36
Smart biomaterials for skeletal aging repair and regeneration
Liang, D., Wang, H., Jiang, Y., Zhang, Z., Zhou, T., Ge, S., Tan, S., Qin, K., Wang, Y., Lin, X., et al. (2026) · Bone Research · doi:10.1038/s41413-026-00505-9 · Cited by 28
“22 Current clinical treatment strategies focus on palliative drug therapy and surgical regenerative therapy.”
Saffarzadeh, M., Hightower, R. C., Talton, J. W., Miller, A. N., Stitzel, J. D., & Weaver, A. A. (2016) · Traffic Injury Prevention · doi:10.1080/15389588.2016.1203429 · Cited by 21
Huang, K., Sun, Y., Chen, X., Tian, F., Fan, C., Gong, Q.-L., & Liu, K.-B. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.9799 · Cited by 20
After the initial fracture in postmenopausal women, where do subsequent fractures occur?
Crandall, C. J., Hunt, R., LaCroix, A. Z., Robbins, J. A., Wactawski‐Wende, J., Johnson, K., Sattari, M., Stone, K. L., Weitlauf, J. C., Gure, T. R., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100826 · Cited by 22
Ishii, Y., Noguchi, H., Sato, J., et al. (2021) · Journal of Orthopaedics · doi:10.1016/j.jor.2021.11.011 · Cited by 18
Lee, D. B., Song, H. J., Paek, Y., et al. (2021) · Nutrients · doi:10.3390/nu14010087 · Cited by 18
Osteoporosis evaluation and treatment recommendations in rheumatoid arthritis
Wysham, K. D., Baker, J. F., & Narla, R. R. (2022) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2022.101757 · Cited by 19
Impact of Menopause in Patients with Multiple Sclerosis: Current Perspectives
Lorefice, L., D’Alterio, M. N., Firinu, D., Fenu, G., & Cocco, E. E. (2023) · International Journal of Women s Health · doi:10.2147/ijwh.s334719 · Cited by 20
Das, C., Das, P. P., & Kambhampati, S. B. S. (2023) · Indian Journal of Orthopaedics · doi:10.1007/s43465-023-01022-1 · Cited by 23
“The primary aims in the management of osteoporosis are to reduce fracture risk, improve bone health, and manage underlying conditions contributing to bone loss [8, 11, 14–16].”
Guimarães, G. C., Coelho, J. B. C., Silva, J. G. O., de Sant’Ana, A. C. C., de Sá, C. A. C., Moreno, J. M., Reis, L. M., & Guimarães, C. S. D. O. (2023) · Osteoporosis International · doi:10.1007/s00198-023-06991-5 · Cited by 21
Granulomatous variant of chronic pigmented purpuric dermatosis: report of two cases.
Wong, W. R., Kuo, T. T., Chen, M. J., et al. (2001) · PubMed · doi:10.1046/j.1365-2133.2001.04304.x · Cited by 18
Osteoporosis and Low Bone Mineral Density in Men with Testosterone Deficiency Syndrome
Gaffney, C., Pagano, M. J., Kuker, A. P., Stember, D. S., & Stahl, P. J. (2015) · Sexual Medicine Reviews · doi:10.1002/smrj.63 · Cited by 23
Baseline age and time to major fracture in younger postmenopausal women
Gourlay, M. L., Overman, R. A., Fine, J. P., Ensrud, K. E., Crandall, C. J., Gass, M. L. S., Robbins, J., Johnson, K., LeBlanc, E. S., Womack, C. R., et al. (2014) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000356 · Cited by 19
Schousboe, J. T., Gourlay, M. L., Fink, H. A., Taylor, B. C., ORWOLL, E. S., Barrett-Connor, E. L., Melton, L. J., Cummings, S. R., & Ensrud, K. E. (2012) · Osteoporosis International · doi:10.1007/s00198-012-1936-7 · Cited by 20
Clinical Management of Vertebral Compression Fractures
Miller, P. D. (2015) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2015.08.006 · Cited by 19
Tang, A., Qian, Y., Liu, S., Wang, W., Xu, B., Qin, A., & Liang, G. (2016) · Nanoscale · doi:10.1039/c6nr00843g · Cited by 18
Bilek, L. D., Waltman, N. L., Lappe, J. M., Kupzyk, K. A., Mack, L. R., Cullen, D. M., Berg, K. E., Langel, M., Meisinger, M., Portelli-Trinidad, A., et al. (2016) · BMC Women s Health · doi:10.1186/s12905-016-0339-x · Cited by 22
Emerging anabolic agents in the treatment of osteoporosis
Lovato, C. M., & Lewiecki, E. M. (2017) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2017.1362389 · Cited by 18
Self-citationImplications of guidelines for osteoporosis and its treatment
Tuck, S. P., Little, E. A., & Aspray, T. (2017) · Age and Ageing · doi:10.1093/ageing/afx197 · Cited by 18
Dalemo, S., Eggertsen, R., Hjerpe, P., Almqvist, E. G., & Boström, K. B. (2018) · Scandinavian Journal of Primary Health Care · doi:10.1080/02813432.2018.1459430 · Cited by 24
Gupta, M., Shah, S., Peterson, S. J., & Baim, S. (2018) · Osteoporosis International · doi:10.1007/s00198-018-4559-9 · Cited by 18
The evolving role of anabolic therapy in the treatment of osteoporosis
Cosman, F. (2019) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000616 · Cited by 20
Self-citationCondorhuamán-Alvarado, P. Y., Pareja‐Sierra, T., Pascual, A. M., Sáez-López, P., Ojeda‐Thies, C., Alarcón-Alarcón, T., Cassinello, C., Pérez‐Castrillón, J. L., Gómez‐Campelo, P., Navarro-Castellanos, L., et al. (2019) · Revista Española de Geriatría y Gerontología · doi:10.1016/j.regg.2019.04.001 · Cited by 22
Toh, L. S., Lai, P. S. M., Wu, D. B., et al. (2019) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2019.09.001 · Cited by 18
“Despite these negative outcomes, only approximately 20% of women who had an osteoporosis-related fracture received either a dual-energy X-ray absorptiometry (DXA) scan, or a prescription to treat osteoporosis [4,5].”
BackgroundDetection and Monitoring of Osteoporosis in a Rat Model by Thermoacoustic Tomography
Chi, Z., Liang, X. Q., Wang, X., Huang, L., & Jiang, H. (2020) · IEEE Journal of Electromagnetics RF and Microwaves in Medicine and Biology · doi:10.1109/jerm.2020.2964152 · Cited by 17
Hip fracture care and national systems: Australia and Asia
Tarrant, S. M., Ajgaonkar, A., Babhulkar, S., et al. (2020) · OTA International The Open Access Journal of Orthopaedic Trauma · doi:10.1097/oi9.0000000000000058 · Cited by 18
Campillo-Sánchez, F., Usategui‐Martín, R., de Temiño, Á. R., Gil, J., Ruiz‐Mambrilla, M., Fernández-Gómez, J. M., Dueñas‐Laita, A., & Pérez‐Castrillón, J. L. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061732 · Cited by 20
Protein intake and osteosarcopenic adiposity in Korean adults aged 50 years and older
Choi, M., & Bae, Y. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05529-3 · Cited by 19
Circulating microRNAs in serum as novel biomarkers for osteoporosis: a case-control study
Shuai, Y., Liao, L., Su, X., et al. (2020) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x20953331 · Cited by 18
Helicobacter pylori Related Diseases and Osteoporotic Fractures (Narrative Review)
Fisher, L., Fisher, A., & Smith, P. N. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103253 · Cited by 20
Miyamura, S., Lans, J., Min, K. S., et al. (2020) · Journal of Shoulder and Elbow Surgery · doi:10.1016/j.jse.2020.09.014 · Cited by 18
Palmowski, Y., Balmer, S., Hu, Z., Winkler, T., Schnake, K. J., Kandziora, F., & Pumberger, M. (2020) · Global Spine Journal · doi:10.1177/2192568220964051 · Cited by 21
“Still, also for these patients kyphoplasty should be considered as a treatment option in cases of persistent pain under conservative therapy, as recommended by current guidelines.(21,22) However, the mean height restoration through kyphoplasty is rather low for OF 2 fractures with an LKA correction of only 0.”
Background
Metadata
- Authors
- Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R.
- Affiliations
- Helen Hayes Hospital (US)
- Brigham and Women's Hospital (US)
- New Mexico Clinical Research & Osteoporosis Center (US)
- Bone Health and Osteoporosis Foundation (US)
- Corresponding author
- Cosman, F.
- Venue
- Osteoporosis International
- Published
- 2014-08-15
- Volume
- 25
- Issue
- 10
- Pages
- 2359-2381
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- PMC
- PMC4176573
- OpenAlex
- W2171709369
- Semantic Scholar
- 91c0d02cdbd4c5dd69ed206e6a0b2b94c9aa0830
- Cited by
- 4,149
- References
- 101
- Citations by year
- 2026: 141 · 2025: 226 · 2024: 267 · 2023: 292 · 2022: 351 · 2021: 415 · 2020: 458 · 2019: 336 · 2018: 311 · 2017: 304 · 2016: 285 · 2015: 246 · 2014: 141
- FWCI
- 242.08
- Type
- journal article
- Language
- en
- Update notices
- correction (2015-05-19)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Osteoporosis International (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Surgery › Hip and Femur Fractures
- Keywords
- osteoporosis, osteoporosis prevention, osteoporosis treatment, bone health, osteoporosis drugs
- MeSH terms
- Aged, Calcium, Dietary, Diet, Female, Humans, Male, Middle Aged, Osteoporosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.